News, stories and opinions for the business innovators of the world.

IVF pioneer Genea sells for more than $250 million

Roger LangsdonMarketing Director

Australian fertility group Genea has been successfully sold to an Asian consortium for more than AU$250 million after disrupting the fertility industry with a range of new IVF technologies.

MW Consortium – comprised of Hong Kong-listed health and wealth conglomerate Mason Group, Chinese online health platform WeDoctor and other investment firms – bought 89.5% of shares in Genea’s Fertility and Biomedx businesses.

The deal comes nine years after Genea, a leading fertility treatment provider for more than 30 years, partnered with Planet Innovation to transform its business from an IVF clinical organization to also marketing IVF technology products.

Led by CEO Tomas Stojanov, Genea launched Genea Biomedx and worked with Planet Innovation to develop a family of industry-changing products that help standardize and automate the IVF process. This includes the award-winning Gavi, the world’s first automated embryo vitrification system (pictured below), and Geri, an incubator with time-lapse embryo imaging.

Gavi instrument in use

Tomas said the deal with MW Consortium would allow for the ongoing growth of Genea as one of the world’s leading integrated IVF companies.

“With the Consortium, Genea is confident it has the right partners for the next stage of its growth, allowing more patients access to our technology and success rates and providing greater opportunities for doctors and staff,” Tomas said.

In an announcement to shareholders in October 2018, Mason Group said investing in Genea would expand its footprint as a leading IVF medical platform in the Asia Pacific region, where demand for IVF technology and services is growing.

“This transaction marks a crucial step towards the Group’s ultimate vision — becoming a world-class conglomerate offering ‘‘Health + Wealth’’ solutions,” the statement read.

Planet Innovation will continue to be Genea Biomedx’s development and manufacturing partner under the new ownership. Co-CEO Sam Lanyon congratulated Genea and MW Consortium on the sale.

“This is a great result for Tomas and the team at Genea. It reflects their commitment to building a successful business that has transformed the industry, and shows that the calculated risk taken in diversifying into IVF technology development has really paid off,” Sam said.

“It’s fantastic that hopeful parents around the world will soon have access to Genea’s fertility expertise and the innovative Genea Biomedx family of products.”

SHARE THIS ARTICLE:
Roger Langsdon Marketing Director
Roger Langsdon

Roger is the Marketing Director at Planet Innovation and a specialist marketing and communications professional with a focus on growing an organisation’s reputation and revenue through strategic marketing and high-impact communications.

Roger Langsdon

Related Articles.

Genea’s IVF deal with Merck secures manufacturing contract for PI

News

Pharmaceutical giant Merck Serono has signed an exclusive deal securing global marketing and commercialization rights to Genea Biomedx’s range of IVF products including Gavi and Geri, which were designed by Genea with development partner, Planet Innovation.

Genea CEO: From idea to Product of the Year

Product Dev

Tomas Stojanov has been an integral part of an extremely successful network of invitro-fertilisation (IVF) clinics in his role as the CEO of fertility group Genea, but his personal dream is to do more. He wanted to change the world of IVF to benefit his company, his industry and most importantly his patients.

How Genea changed the world of IVF through automation

Product Dev

Despite 30 years of IVF practice the process of freezing human embryos, known as vitrification, has remained extremely manual and susceptible to errors and inconsistencies by embryologists. In 2009, Genea Biomedx teamed up with Planet Innovation to solve this challenge by automating IVF vitrification and finally making the process consistent and standardised for labs around the world.

PI broadens Board experience with two new non-executive directors

News

Medtech industry veteran Euan Pizzey and accomplished executive Lisa Hennessy have been appointed to the PI Board to help achieve our vision of becoming Australia’s leading incubator of high-growth technology companies.

News

Genea’s IVF deal with Merck secures manufacturing contract for PI

Pharmaceutical giant Merck Serono has signed an exclusive deal securing global marketing and commercialization rights to Genea Biomedx’s range of IVF products including Gavi and Geri, which were designed by Genea with development partner, Planet Innovation.